The second clinical trial has been conducted in transfusion-dependent thalassemia main patients with chronic anemia. Patients are randomized into a crossover style and can receive transfusion support, in random sequence separately, with both conventional and INTERCEPT RBCs over 12 months approximately. Target enrollment is 70 patients, and the principal endpoints are hemoglobin utilization and immunogenicity with do it again exposure . Hemoglobin utilization was selected as the principal efficacy endpoint as it represents the power of transfused RBCs to oxygenate tissues, to persist in circulation, also to suppress endogenous erythropoiesis.‘Dr. Alan Bernstein, the executive director of the Global HIV Vaccine Enterprise, said the quickness with which a successful HIV vaccine is created would be influenced by the funding available. ‘Today, as part of your, I am confident an HIV vaccine will be developed. How quickly depends upon the money and ideas,” he said . Tuesday Full Results From Thailand Helps Vaccine Trial Released Also through the AIDS vaccine conference, researchers presented a complete analysis of the results from an experimental HIV vaccine examined in Thailand, the LA Times reports . The full results of the study, published online Tuesday in the New England Journal of Medicine, ‘include two additional analyses that recommend the vaccine is beneficial merely, rather than providing definitive proof,’ the Associated Press reviews.